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Background: Little is known about the long-term success of non-drug therapies for treating dementia, especially
whether the effects are sustained after therapy ends. Here, we examined the effects of a one-year multimodal
therapy 10 months after patients completed the therapy.
Methods: This randomised, controlled, single-blind, longitudinal trial involved 61 patients (catamnesis: n = 52) with
primary degenerative dementia in five nursing homes in Bavaria, Germany. The highly standardised intervention,
MAKS, consisted of motor stimulation, practice of activities of daily living (ADLs), and cognitive stimulation. Each
group of 10 patients was treated for 2 h, 6 days a week for 12 months. Control patients received standard nursing
home care. At baseline, at the end of therapy (month 12), and 10 months thereafter (month 22), cognitive
functioning was assessed using the cognitive subscale of the Alzheimer’s Disease Assessment Scale, and the ability
to perform ADLs was assessed using the Erlangen Test of Activities of Daily Living.
Results: During the therapy phase, the MAKS patients maintained their cognitive function and ability to carry
out ADLs. After the end of therapy, both the control and the MAKS groups deteriorated in both their
cognitive function (control, p = 0.02; MAKS, p < 0.001) and their ability to carry out ADLs (control, p < 0.001;
MAKS, p = 0.001). However, in a confound-adjusted multiple regression model, the ability of the MAKS group
to perform ADLs remained significantly higher than that of the control group even 10 months after the end
of therapy (H0: βMAKS + βMAKS month 22 = 0; χ2 = 3.8568, p = 0.0496). Cohen’s d for the difference between the
two groups in ADLs and cognitive abilities 10 months after the end of therapy was 0.40 and 0.22, respectively.
Conclusions: A multimodal non-drug therapy of dementia resulted in stabilisation of the ability to perform
ADLs, even beyond the end of therapy. To prevent functional decline for as long as possible, therapy should
be performed continuously until the benefit for the patient ends. Follow-up studies on larger numbers of
patients are needed to definitively confirm these results.
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Alzheimer’s dementia has been treated with drug therapy,
non-drug therapy, and a combination of the two therapy
types. In recent years, some studies have demonstrated
the efficacy of non-drug therapy [1,2]. Unimodal interven-
tions usually target cognition or the neuropsychological
symptoms of dementia, and most available data are used
to assess the efficacy of cognitive approaches [3]. However,
the greatest effects of non-drug therapies in the treatment
of Alzheimer’s dementia are achieved with multimodal
therapy [1,4,5]. Cognitive training combined with treat-
ment with acetylcholinesterase inhibitors has also been
used and often brings better results than drug therapy
alone [6,7], but intensive non-drug therapies alone also
appear to be superior to drug therapy alone [7].
Little is known about the sustainability of any of these
therapeutic effects. Whereas it would be expected that the
cognitive performance of Alzheimer patients who respond
to drug therapy will inevitably deteriorate when the medi-
cation is withdrawn [8,9], preliminary evidence indicates
that non-drug therapies may result in greater sustainability
of cognition and the ability to carry out activities of daily
living (ADLs) [10,11]. Theoretically, this can be explained
in that non-drug therapies strengthen abilities that the
dementia patient can apply in everyday life and thus lead
to a self-strengthening or more-or-less continued self-
training. Yet no high-quality methodological studies have
addressed this assumption. In a recent Cochrane review up
to the end of 2011 [12] on the efficacy of cognitive training,
15 randomised controlled trials (RCTs) met the criteria for
inclusion in the review. Only 4 of these studies examined
the efficacy of the intervention after the end of therapy—3
during the first 3 months, and 1 at 10 months after the end
of therapy. In the last study [6], neither cognition nor the
ability to perform ADLs differed significantly between the
therapy and control groups 10 months after the end of
therapy [cognitive subscale of the Alzheimer’s Disease
Assessment Scale (ADAS-cog): p = 0.66, SMD 0.12 (−0.41;
0.66); Texas Functional Living Scale: p = 0.12, SMD 0.43
(−0.30; 0.97)]. In addition to the 8-week cognitive training
of the therapy group, all patients received the acetylcholin-
esterase inhibitor donepezil for the entire study period. In
the re-analysis of the 3 other studies that examined the
efficacy 1 to 3 months after the end of therapy, a significant
effect on cognition was found (p = 0.05) [12]. These 3 stud-
ies did not examine ADLs. Further high-quality methodo-
logical studies of the sustainability of non-drug therapies
are needed, not only because of their importance for cost
savings in the health system [13].
In a blinded RCT design, we have demonstrated the
efficacy of our multimodal activation therapy developed
for institutionalised patients [14] with respect to cogni-
tion and the ability to carry out ADLs after a 12-month
therapy [5,15]. In the subsequent follow-up studyreported here in which we address the sustainability of
the therapeutic effects, all of the patients still living 10




Ten months after the end of our randomised, controlled,
single-blind longitudinal trial of a multicomponent, non-
pharmacological group therapy known as MAKS, we
examined the efficacy of the therapy with dementia
patients in five German nursing homes [5]. The MAKS
therapy phase lasted 12 months, beginning in December
2008 and ending in December 2009. During this period,
the MAKS group received 2h multimodal therapy 6 days a
week, whereas a control group received the standard nurs-
ing home care. Both groups were examined with respect
to cognitive function and their ability to perform ADLs
prior to starting therapy (baseline), at the time therapy
ended (month 12), and 10 months after the end of therapy
(month 22).
Sample
Ninety-eight patients included in the original study fulfilled
the following inclusion criteria: presence of primary degen-
erative dementia according to ICD-10 (F00, F03, or G30)
and as confirmed by the attending physician; fewer than 24
points on the Mini-Mental State Examination (MMSE)
[16]; and written informed consent of the patient or, when
necessary, the patient’s legal guardian prior to baseline. This
means that most of the patients are supposed to suffer from
Alzheimer’s disease or a mixed form of Alzheimer/vascular
dementia. Patients with pure vascular dementias were
excluded. Of the approximately 400 residents who were
positively screened for dementia, only 47 had to be
excluded because of non-degenerative dementia according
to the attending physician (see Figure 1). The sample
therefore represents about 90% of the nursing home resi-
dents with cognitive deficits. The form sheet, all legal con-
ditions, and the study design were examined by the Ethics
Committee of the Medical Faculty of the University
of Erlangen. Approval was granted on 10 July 2008
(Registration Number 3232). Exclusion criteria were as
follows: vascular (F01) or secondary (F02) dementia
according to ICD-10; the presence of other neurological/
psychiatric disease(s) that could explain the patient’s de-
cline in cognitive function; very high nursing care needs
(i.e. care level 3, which is the highest level of the three-
level scale currently used to determine eligibility for nurs-
ing care benefits in Germany); deafness; or blindness.
Taking medication of any type did not affect inclusion or
exclusion in our study (see Table 1 for medication taken).
Of the 98 patients included, 35 met the dropout criteria
during the intervention period, and 2 had to be excluded
553 nursing home residents 
assessed for eligibility (i.e. all 
residents of 5 nursing homes 
independent of diagnosis) 
434 excluded  
     9 blind 
     5 deaf 
     8 other reasons 
   20 physical reasons (e.g. dialysis)  
   39 unwilling to participate 
   47 no degenerative dementia 
according to attending physician  
   48 unable to communicate 
 128 MMSE score >24 
 130 care level 3/bedridden
31 analysed as treated 
19 discontinued study participation 
Reasons for drop-out: 
3 died  
4 refused  
5 care level 3/bedridden 
7 absent more than 3 weeks 
50 allocated to intervention group, 
which received MAKS therapy 
16 discontinued study participation 
Reasons for drop-out: 
6 died 
1 refused 
6 care level 3/bedridden 
3 moved away 
48 allocated to control group, which 
received treatment as usual.
30 analysed as treated 
2 persons excluded: late information 
provided by physician about former 









(max. 20 persons per 
nursing home) 
30 analysed  22 analysed 
22-month analysis 
22-month follow-up 
1 lost to follow-up 
Reason: participant died 
8 lost to follow-up 
Reason: participants died 
Figure 1 CONSORT flowchart.
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12). Nine patients died in the 10 months between the end
of therapy and the follow-up study. Hence, the follow-up
analysis comprised 52 patients—22 in the control group
and 30 in the MAKS intervention group (Figure 1).
Patients
The number of patients analysed consisted of the number
eligible at each time point (Figure 1). All patients who
completed 12 months of either the MAKS therapy or the
control group (standard nursing home care) were exam-
ined at the end of the therapy at month 12 (n = 61), andthose who were still alive 10 months after the end of
therapy were examined in the follow-up analysis at
month 22 (n = 52). The patients who completed the
study did not differ at baseline from those that were
excluded in terms of age (t-test: p = 0.58), cognition
(MMSE: p = 0.27; ADAS-cog: p = 0.14), and ability to
carry out ADLs (Erlangen Test of Activities of Daily
Living; E-ADL test: p = 0.08).
The characteristics of the 52 patients who completed
the follow-up analysis are summarised in Table 1. Patients
were on average 84 years old; 83% were female. Only 6 of
the 52 patients were taking anti-dementia drugs; 3 were in
Table 1 Characteristics of the patients participating through the follow-up analysis
Characteristics MAKS group Control group Total
(n = 30) (n = 22) (n = 52)
Age, mean (SD) 84.1 (5.02) 84.64 (5.45) 84.33 (5.16)
Women, no. (%) 27 (90.0) 16 (72.7) 43 (82.7)
Educational attainment, no. (%)
No school completed 4 (13.3) 2 (9.1) 6 (11.5)
Lower secondary school (Hauptschule;
through grade 9)
21 (70.0) 16 (72.7) 37 (71.2)
Secondary modern school (Realschule;
through grade 10)
4 (13.3) 1 (4.5) 5 (9.6)
University-preparatory secondary school
(Gymnasium; through grade 13)
0 (0) 1 (4.5) 1 (1.9)
Information lacking 1 (3.3) 2 (9.1) 3 (5.8)
Marital status, no. (%)
Married 2 (6.7) 5 (22.7) 7 (13.5)
Widowed 22 (73.3) 16 (72.7) 38 (73.1)
Divorced 0 (0) 1 (4.5) 1 (1,9)
Single 6 (20.0) 0 (0) 6 (11.5)
MMSE mean (SD) 15.57 (4.83) 14.14 (5.45) 14.96 (5.1)
NOSGER subscale mood, mean (SD) 10.43 (3.13) 9.41 (2.99) 10.0 (3.08)
Charlson comorbidity indexa, mean (SD) 0.95 (1.34) 1.0 (1.34) 0.97 (1.33)
Use of anti-dementia medications, no. (%) 3 (10.0) 3 (13.6) 6 (11.5)
Medication scoreb, mean (SD) −1.57 (1.81) −1.82 (1.87) −1.67 (1.82)
Abbreviations: MMSE, Mini-Mental State Examination; NOSGER, Nurses’ Observation Scale for Geriatric Patients; ADAS-cog, Alzheimer’s Disease Assessment Scale,
subscale cognition; E-ADL test, Erlangen Test of Activities of Daily Living.
a Charlson comorbidity index: Effect of comorbidities (i.e. in addition to dementia) on mortality rate. A condition is assigned a score according to the mortality risk
associated with it. One-year mortality increases from 12% (index = 0) to 85% (index ≥ 5) as the score increases.
b Medication score: mean value of the sedating or activating (side-)effect of all medications taken by the patient, calculated using all prescribed medications,
including anti-dementia drugs. To calculate these effects, two experts from the Department of Clinical Pharmacology at the University of Erlangen rated all
medications in terms of their sedating or stimulating effect or side effects using a five-step scale: –2 (very sedating), –1 (sedating), 0 (neither sedating nor
stimulating), +1 (stimulating), +2 (very stimulating).
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MMSE score was on average 15 points.
Treatment conditions
MAKS is a multicomponent group therapy consisting
of tasks organised into three categories—motor stimu-
lation (M), ADLs (A), and cognition (K)—preceded by
a short introduction consisting of what we called a
spiritual element (S). Each daily session began with
this introduction, which lasted approximately 10 min
and was designed to help the dementia patients feel
part of the group. This was followed by about 30 min
of motor exercises. After a 10-min break, the patients
spent approximately 30 min completing a variety of
cognitive tasks. This was followed by about 40 min of
ADLs [for further information, see [5]].
The members of the control group received the
standard care offered in each nursing home and were
free to participate in any of the regular, non-MAKS
activities offered at the nursing home. Patients in thecontrol group participated in an average of two of these
non-MAKS activities per week. Also, patients in the
MAKS group were free to take part in these non-
MAKS activities in addition to MAKS and did so once
a week on average. The study did not interfere in any
way with the patients’ existing pharmacological treat-
ment or nursing care.Implementation of treatment
MAKS therapy was conducted in each nursing home by
two therapists and one aide from Monday to Saturday from
9:30 am to 11:30 am for 12 months. The therapists were
registered geriatric nurses. Each therapy group consisted of
10 dementia patients. Therapists and aides received a stan-
dardised handbook from the central study site describing in
detail the steps to be taken on each day of therapy [14].
This guaranteed that the same tasks would be performed
on any given day at each nursing home [for further infor-
mation, see [5]].
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The cognitive and ADL-abilities of the patients were
recorded by independent evaluators, who were blinded
to treatment allocation and were not part of the nursing
home staff. The patients were evaluated before the ther-
apy commenced (baseline), at the end of the 12-month
therapy (month 12), and 10 months after completion of
the therapy (month 22), with all patients having the
standard nursing home care during this latter period.
Data were pseudonymised and submitted to the central
study site.
Cognitive abilities were measured using the ADAS-cog
[17]. The scale ranges from 0 to 70, with higher scores
indicating greater deficits (Cronbach’s α = 0.82; construct
validity, correlation with MMSE −0.81).
The ability to carry out ADLs was measured using the
E-ADL test [18]. This is a performance test of fundamen-
tal abilities of daily living under standardised conditions
and includes pouring a drink, cutting a piece of bread,
opening a little cupboard, washing one’s hands, and tying
a bow. The range is from 0 to 30, with higher scores indi-
cating a greater ability to carry out the activities (α = 0.77).
Study coordinators recorded each patient’s age, gender,
educational attainment, family status, and nursing care
needs at baseline. The nursing staff rated symptoms of
depression among the patients at baseline using the mood
subscale of the Nurses’ Observation Scale of Geriatric
Patients (NOSGER) [19] (test-retest reliability: 0.85; cor-
relation with the Geriatric Depression Scale: rS = 0.63).
We also calculated the effect of any previous medical
diagnoses on the mortality rate using the Charlson
comorbidity index [20]. Potential bias resulting from
pharmacological interventions was accounted for by
using a medication score (sedative/stimulating effect of
all medication) (see Table 1).Statistical analysis
We statistically analysed the data of all patients who com-
pleted the primary intervention period of 12 months either
in the MAKS group or in the control group (n = 61). In the
analysis of the follow-up data, we made attempts to record
outcome variables for all patients who completed the inter-
vention period and who were still alive 10 months after the
end of therapy (n = 52). If more than 20% of the items on
the ADAS-cog subscale or the E-ADL test were missing
for any given patient (e.g. because of his or her refusal to
complete the test), the score was calculated according to
the expectation-maximum (EM) algorithm. Under these
conditions, imputation at the 10-month follow-up was
necessary in 4 cases. The scores for patients who died dur-
ing the 10-month interim period without therapy (n = 9)
were not imputed. The number of patients eligible for the
analysis in the multiple regression models was 61 at theend of the therapy (at month 12) and 52 after the 10
months following the therapy (at month 22).
To describe the course, t-tests for dependent samples
were calculated for both groups for the two time periods.
The first period was the 12-month therapy period (from
baseline to month 12), and the second period was the
10-month interim without therapy between evaluations
(from month 12 to month 22). Model diagnostics of the
differences revealed no deviation from a normal distribu-
tion. Cohen’s d with pooled standard deviation [21] was
calculated as the measure of effect size.
Differences between the groups were calculated with
multiple analyses to adjust for possible confounders; mul-
tiple linear mixed models were computed. We computed
two separate models, one for the E-ADL test score and
one for the ADAS-cog score. For the analysis, we adjusted
the score at months 12 and 22 for the baseline values
(score at month 12 – baseline score, and score at month
22 – baseline score). We then built a variable that con-
tains both measurements for each patient (where avail-
able) and used another variable to reflect the time of
measurement (“repeated measurements”). We included
the following independent variables: intervention group
(MAKS vs. control), observation time (month 12 vs.
month 22), age of the patient, medication score, NOSGER
subscale mood, anti-dementia medication, and the inter-
action of the intervention group and observation time to
account for possible changes of the group effect over
time. The “nursing home” entered the model as a random
effect. Model diagnostics revealed no substantial deviation
from the model assumptions.
In a sensitivity analysis, we additionally included a ran-
dom slope for time to account for possible non-systematic
variations over time. For the analyses, we used the statistical
software packages R [22] and SPSS [23]. P-values smaller
than 0.05 indicate significant effects.
Results
In the course of the 12 months of therapy, the cognitive
and ADL-abilities of the patients in the control group
(n = 30) decreased significantly (t-test for dependent sam-
ples; ADAS-cog: baseline, 35.6 ± 14.8 SD; at month 12,
40.8 ± 17.0, p = 0.039; E-ADL test: baseline, 24.3 ± 5.6; at
month 12, 21.5 ± 7.4, p = 0.005). By contrast, these abil-
ities of the MAKS group (n = 31) remained stable during
this time (ADAS-cog: baseline, 32.6 ± 11.5; at month 12,
32.5 ± 15.3, p = 0.99; E-ADL test: baseline, 26.6 ± 5.1; at
month 12, 26.3 ± 14.8, p = 0.72; see also [5]). The cogni-
tive and ADL-abilities of patients in both groups (n = 52)
deteriorated significantly between the end of therapy
and the follow-up evaluation after 10 months (MAKS
group: ADAS-cog: 40.06 ± 17.04, p = <0.001; E-ADL
test: 20.90 ± 10.08, p = 0.001 / control group: ADAS-cog:





















Figure 3 Median ADAS-cog values over time. Median ADAS-cog
values in the MAKS and control groups over time together with the
corresponding notched boxplots. Higher scores indicate greater
deficits. Boxplots represent the distribution of raw data values. Non-
overlapping notches are a (rough) indicator of significantly different
medians [28].
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evaluation 10 months after the end of therapy, Cohen’s d
was 0.40 for ADL-abilities and 0.22 for cognitive abilities.
In the confound-adjusted multiple regression model with
the random effect of “nursing home” (see Additional file 1),
the E-ADL test score of the MAKS group remained signifi-
cantly higher than that of the control group even 10
months after the end of therapy (H0: βMAKS + βMAKS month
22 = 0; χ
2 = 3.86, p = 0.0496). The effect of therapy on the
ability to carry out ADLs over time was not only sustain-
able but even increased slightly over time after the end of
the MAKS therapy, as can be seen in the widening of the
solid lines in Figure 4.
In a sensitivity analysis, we additionally adjusted for a po-
tential auto-correlation between the time points and thus
included a random slope for time. In this case, the effect of
MAKS therapy 10 months after the end of therapy was no
longer significant (χ2 = 2.49, p = 0.116). Despite the lack of a
significant difference in this case, the effect estimates
revealed the same structure as depicted in Figure 4, i.e. the
effects of the model with the interaction indicate that the
effect of therapy (month 12) was not only preserved but
had a slight tendency to become even more pronounced 10
months after the therapy (month 22).
As for the ADLs, we used a confound-adjusted model
with a random effect of “nursing home” to evaluate the

















Figure 2 Median E-ADL test values over time. Median E-ADL
test values in the groups MAKS and control over time together
with the corresponding notched boxplots. Lower scores indicate
greater deficits. Boxplots represent the distribution of raw data
values. Non-overlapping notches are a (rough) indicator of







































Figure 4 Estimated changes of E-ADL test score compared to
baseline using a random effects model. Higher scores indicate
better abilities to perform ADLs. The solid lines represent effect
estimates from a model with an interaction term for time and
group, i.e. where the group effect can change over time. The
dashed lines indicate a model without interaction. In this case, the
group effect is forced to stay constant (as can be seen from the
parallel dashed lines from month 12 to month 22).
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a lasting effect of MAKS therapy on ADAS-cog
(H0: βMAKS + βMAKS month 22 = 0; χ
2 = 1.15, p = 0.282).
One can even deduce from Figure 5 that the groups
were slowly converging.
The sensitivity analysis with an additional random
slope of time did not change the result (MAKS vs. con-
trol at month 22: χ2 = 0.88, p = 0.347).
Discussion
The present study addressed whether the positive effects
on cognition and the ability to carry out ADLs of a
12-month multimodal therapy of dementia patients are
sustainable 10 months after the end of therapy. This study
is thus one of the first RCTs to systematically examine the
sustainability of the effects of a non-drug therapy in de-
mentia patients. Our results using a confound-adjusted
multiple regression model indicated that the positive
effects of the group therapy (i.e. therapy group vs. control
group) on the ability to carry out ADLs were indeed
sustainable. This effect was still existent but no longer sta-
tistically significant when controlled for a random subject-
specific slope. Such a finding is unique in the literature.
To date, only two randomised studies have addressed the
sustainability of non-drug therapy procedures on cogni-







































Figure 5 Estimated changes of ADAS-cog compared to baseline
using a random effects model. Higher scores indicate greater
deficits. The solid lines represent effect estimates from a model with
an interaction term for time and group, i.e. where the group effect
can change over time. The dashed lines indicate a model without
interaction. In this case, the group effect is forced to stay constant
(as can be seen from the parallel, dashed lines from month 12 to
month 22).In a recent study on dementia patients living at home,
Giordano et al. [24] showed that the success of therapy
combining cholinesterase inhibitors and a 3-week Reality
Orientation Training (ROT) could still be demonstrated 2
months after the active intervention phase as long as
family members continued the ROT. Control patients
were treated only with cholinesterase inhibitors. The
patients of the therapy group profited, however, only in
the cognitive area; effects on their ability to carry out ac-
tivities of daily living were never observed. Moreover, ther-
apy was never withdrawn as medication was maintained
in both the ROT and control groups, and caregivers of the
test group were asked to continue ROT at home, even if
this potentially occurred in a less systematic form. One
problem that this study had is the short time frame, as
even placebo effects can last up to 9 months as Ito et al.
[25] demonstrated in a meta-analysis.
Chapman et al. [6] studied the efficacy of a combination
therapy consisting of donepezil and cognitive stimulation
therapy in a controlled randomised study of 54 dementia
patients. The control group received donepezil alone. The
parameters were cognition, ability to carry out ADLs, and
neuropsychiatric symptoms. The therapy was conducted
once a week for 2 months. With the two scales used
(ADAS-cog and Texas Functional Living Scale TFLS),
which are comparable to those of our study, the authors
found a significant decline in abilities in both the test and
control groups over the course of a year. No effects on cog-
nition or the ability to perform ADLs could be demon-
strated at the end of therapy or 10 months after ending
therapy. However, an advantage of the combined therapy
was found in the MMSE and some subscales of the Neuro-
psychiatric Inventory (NPI) 10 months after the end of
therapy. As effects of pharmacological treatment have been
shown elsewhere to last less than 12 months [25], the dif-
ferences between the treatment and control groups are
more likely related to the cognitive stimulation. The lack of
effects on the ADAS-cog and the TFLS of this therapy may
be attributable to its low intensity (8 sessions over 2
months), which is considerably less intensive than our
MAKS therapy (about 300 sessions over 12 months). Other
studies examining the sustainability of non-drug therapy
procedures have usually addressed the neuropsychological
symptoms of dementia, such as mood and behaviour e.g.
[26,27] or are of limited reliability due to the small number
of patients [10,11].
In the main analysis, we found a long-term effect of the
MAKS therapy on the ability to carry out ADLs but not on
cognition. Future studies should test whether ADL training
will preserve the self-reliance of the participating home
residents more than that of the control group. This in turn
would mean that ADLs are performed independently to a
greater extent and are thus automatically trained further.
By contrast, the long-term effect of MAKS therapy on
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between the control group and therapy group was smaller
10 months after the end of therapy, and the effect of the
therapy was no longer demonstrable in multivariate ana-
lyses. Compared to a strictly pharmaceutical therapy, a
non-drug therapy thus appears to offer the potential of an
effect that promotes independence in everyday living that
lasts beyond the term of therapy, even if the positive effect
on cognitive functions did not continue after therapy
ended. Because the cognitive abilities as well as ADLs
abilities were preserved in the MAKS group during therapy,
a continuous therapy could perhaps stabilise both abilities
even longer.
A limitation of the present study is the number of
patients. After 22 months, only a relatively small sample
number of patients remained (n = 52), owing in part to
the high mortality rate in the age spectrum examined.
The small number of cases is probably also the reason
why the model in the sensitivity analysis with a random
slope did not attain significance for the ability to carry
out ADLs, especially since the variation of the measured
E-ADL test scores increased over time (see Figure 2).
Also, results are valid only for patients with degenerative
dementias such as Alzheimer’s dementia or dementia of
the mixed form. Effects on persons with vascular demen-
tia were not examined. Another limitation might be the
use of the ADAS-cog as the outcome instrument for cog-
nition. The ADAS-cog does not have parallel versions for
test-retest settings; stabilisation might therefore be due to
learning effects rather than due to therapy. However, this
effect would be the same in the control and therapy
groups. Thus, differences between the groups cannot be
explained by learning effects. Further studies with a
considerably larger number of patients, an extended
follow-up period, and more sensitive test items are thus
necessary to verify the results shown here.
One strength of the study is the strict RCT design used
during the therapy phase. To our knowledge, our study is
thus the first to examine the sustainability of an exclusively
non-drug therapy of dementia after completion of the ac-
tive therapy phase. Our method is also notable in that all
dependent variables were recorded blindly by testing and
not, as is often the case, by using outside assessment.
Conclusions
Our intensive multimodal therapy was elsewhere shown to
be effective in the treatment of dementia with regard to
both cognitive functioning and the ability to perform ADLs
with greater effect sizes for patients with mild to moderate
dementia [5]. This study of the long-term effects of a non-
drug therapy showed that upon withdrawal of non-drug
therapy, the ability to perform ADLs—as compared to
cognitive functioning—tended to be more focused on “self-
preservation”. Hence, intensive multimodal therapy shouldbe started as early as possible to maintain the abilities still
present in the dementia patient. It is also especially impor-
tant to apply the therapy continuously to retain for as long
as possible not only the ADL-abilities but also the cognitive
functions, and thus to retain the independence of people
with dementia. Future research on this topic including a
larger sample size, even longer follow-up periods, and per-
haps different outcome measurements should be performed
to support the findings.
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